A Phase I Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Replication-defective HIV-1 Vaccine (HIVAX) in HIV-1 Infected Subjects Receiving Highly Active Antiretroviral Therapy

Trial Profile

A Phase I Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Replication-defective HIV-1 Vaccine (HIVAX) in HIV-1 Infected Subjects Receiving Highly Active Antiretroviral Therapy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs HIV vaccine (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Acronyms GCHT01
  • Sponsors GeneCure
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Apr 2017 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017.
    • 30 Mar 2016 According to a GeneCure media release, results from this trial were published in the March issue of Vaccine journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top